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Abstract
Background: In order to explore a pre-clinical method to evaluate if [18F]FDG is valid for monitoring
early response, we investigated the uptake of FDG in Multicellular tumour spheroids (MTS) without and
with treatment with five routinely used chemotherapy agents in breast cancer.
Methods: The response to each anticancer treatment was evaluated by measurement of the [18F]FDG
uptake and viable volume of the MTSs after 2 and 3 days of treatment.
Results: The effect of Paclitaxel and Docetaxel on [18F]FDG uptake per viable volume was more evident
in BT474 (up to 55% decrease) than in MCF-7 (up to 25% decrease).
Doxorubicin reduced the [18F]FDG uptake per viable volume more noticeable in MCF-7 (25%) than in
BT474 MTSs.
Tamoxifen reduced the [18F]FDG uptake per viable volume only in MCF-7 at the highest dose of 1 μM.
No effect of Imatinib was observed.
Conclusion: MTS was shown to be appropriate to investigate the potential of FDG-PET for early breast
cancer treatment monitoring; the treatment effect can be observed before any tumour size changes occur.
The combination of PET radiotracers and image analysis in MTS provides a good model to evaluate the
relationship between tumour volume and the uptake of metabolic tracer before and after chemotherapy.
This feature could be used for screening and selecting PET-tracers for early assessment of treatment
response.
In addition, this new method gives a possibility to assess quickly, and in vitro, a good preclinical profile of 
existing and newly developed anti-cancer drugs.
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Positron emission tomography (PET) is a multi-purpose
non-invasive imaging technique with a wide range of
applications both in vivo and in vitro [1]. In clinical
oncology PET has been used for diagnosis, staging, and
restaging after treatment or recurrence of different malig-
nancies, including breast cancer [2-4].
PET with 2-fluorine-18-fluoro-2-deoxy-D-glucose
([18F]FDG-PET) represents a functional imaging modality
that is based on metabolic characteristics of malignant
tumours [5]. The uptake of [18F]FDG into tissue reflects
both transport and phosphorylation of glucose by viable
cells. Quantitative assessment of tumour metabolism by
[18F]FDG-PET represents a novel approach in screening
the response of malignant tumours to chemotherapy [6-
12].
Early assessment of response would greatly benefit man-
agement of patients receiving chemotherapy by assuring
continuance of effective therapy in those who respond or
instituting alternative therapy in those who do not [11]. It
would also be beneficial if patients with unresponsive
tumours could be identified at a much earlier stage,
thereby avoiding the use of ineffective, toxic and expen-
sive treatment. As an innovative instrument for therapy
monitoring, PET provides a more timely assessment of the
efficacy of specific therapies, which would then offer a sig-
nificant alteration in clinical management.
However, PET with a tracer for cellular function might not
necessarily allow an early assessment of treatment
response. A prerequisite for this is that the treatment
affects biochemical cascades leading to antitumoral
actions, and that the action record by the PET tracer is in
some way mechanistically coupled to these cascades. E.g.
inhibition of growth by alkylation of DNA might not nec-
essarily lead to inhibition of [18F]FDG uptake and phos-
phorylation. Therefore it is not advisable to start a clinical
trial with an antitumoral agent expecting PET to be used
for treatment monitoring, without an initial assessment
that PET can indeed serve this task.
MTSs represent a transitional level between cells growing
as an in vitro monolayer and solid tumours in experimen-
tal animals or patients [13-16]. It has been confirmed that
the cytology and the morphology of spheroids resembles
that of experimental tumours in mice and natural
tumours in humans before neovascularisation. Hence the
MTS model has gained fundamental importance in thera-
peutically oriented investigations, as in the areas of radio-
therapy, chemotherapy, photodynamic therapy,
radioimunotherapy, and cell- and antibody-based immu-
notherapy [17-19].
Here MTS model was used to investigate the capability of
[18F]FDG-PET to monitor early response of five commer-
cially available and routinely used chemotherapy agents.
Microscope-image-analysis of MTS was implemented to
relate cell viability to [18F]FDG-uptake. We found the
combination of morphological imaging and assessment
of metabolic condition of tumour improved the quantita-
tive knowledge about tumour and treatment response.
Materials and methods
Cell lines
1. Cells of the MCF-7 human breast cancer line (European
Collection of Cell Culture) were grown in MEM/EBSS sup-
plemented with 10% FCS, 1 mM sodium pyruvate, 2 mM
L-glutamine, 1% non-essential amino acid and 5% peni-
cillin (Tamro). The medium was changed twice weekly
and cells were maintained in exponential growth phase.
2. Cells of the BT474 human breast cancer line (American
Type Culture Collection) were grown in DMEM-high glu-
cose supplemented with 10% FCS, 1 mM sodium pyru-
vate, 2 mM L-glutamine and 5% penicillin (Tamro). The
medium was changed twice weekly and cells were main-
tained in exponential growth phase.
Multicellular tumour spheroid
The tumour cells were trypsinized from the stem monol-
ayer culture. Cell suspensions were then seeded in 24-
well, 1% agarose-coated spheroid plates, with approxi-
mately 50,000 cells per well for MCF-7 cell line and
10,000 cells per well for BT474 cell line. The spheroids
were kept at 37°C with 5% CO2, and grown for five days.
Image analysis (SASDM)
Images of MTSs were recorded and analyzed in semi-auto-
mated size determination software (SASDM)[20]. Total,
necrosis and viable volume of each MTS was calculated by
the program.
18F-labeled 2-Fluoro-D-glucose ([18F]FDG) uptake
The MTSs were incubated for 50 min at 37°C with 0.5 ml
medium per well containing 3MBq [18F]FDG[21], and
then washed 3 × 5 min with medium (1 ml/well). Finally
MTSs with 20 μl washing medium were transferred to 5 ml
tubes and [18F]FDG uptake was evaluated in a calibrated
well γ-counter. A 20 μl sample of the incubation medium
was measured as reference, and 20 μl from the last wash
medium was measured as background control.
The [18F]FDG-uptake in aggregates was defined as:
Total uptake = (Act conc. (Bq/ml) of aggregate) / (Act
conc. (Bq/ml) of reference)Page 2 of 8
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To ensure the physiological validity of [18F]FDG uptake in
MTS, a number of basic experiments were performed:
• Temperature dependence of [18F]FDG uptake. The
[18F]FDG uptake experiments were performed with two
different incubation temperatures: 4°C and 37°C.
• Competition Experiment. Glucose concentration in the
growing culture medium was 5 mM. To perform the com-
petition experiment, unlabeled extra glucose was diluted
in the growing culture medium with a concentration of 0
mM (for the control group), 5 mM, 10 mM and 20 mM.
Culture medium was replaced by glucose/ [18F]FDG-con-
taining culture medium. After 50 min incubation the
[18F]FDG uptake was measured.
• Inhibition Experiment. The MTSs were pre-incubated with
four different concentrations of an inhibitor of glucose
transport, Cytochalasin-B; 0 μM (for control group), 10
μM, 25 μM and 50 μM followed by 50 min [18F]FDG incu-
bation.
• Insulin-mediated [18F]FDG uptake. The MTSs were pre-
incubated with or without (control group) 10 μM insulin
followed by 50 min [18F]FDG incubation.
It is noticeable that the basic experiments were performed
only on MTSs of MCF-7 cell line. In each experimental set-
up six MTSs in one 24-well plate were referred to as one
group and the experiments were repeated three times.
Anticancer treatment
The anticancer agents used were:
• Paclitaxel (an inhibitor of microtubule remodelling)
• Docetaxel (also an inhibitor of microtubule remodel-
ling)
• Doxorubicin (an anthracycline antibiotic)
Competition experiment (upper left) Temperature dependence of [18F]FDG -uptake (upper right) Inhibition experiment (l wer left) Insulin dependenc  glucose transport (lower right)Figur  1
Competition experiment (upper left) Temperature dependence of [18F]FDG -uptake (upper right) Inhibition experiment 
(lower left) Insulin dependence glucose transport (lower right).Page 3 of 8
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• Imatinib (a protein-tyrosine kinase inhibitor).
Each drug was diluted in the growing culture medium to
a concentration of 10 nM, 100 nM and 1 μM. Treatment
begun at day five of MTS growth with change of the cul-
ture medium to the drug-containing medium. After 1 h
the medium was renewed, and the MTSs remained in drug
containing medium for 2–3 days.
For the MCF-7 cell line, each group included 6 replicates
and the experiments were repeated twice.
For the BT474 cell line, each group included 4 replicates
and the experiments were repeated three times.
The response to each anticancer treatment was evaluated
by measurement of the [18F]FDG uptake and viable vol-
ume of the MTSs after 2 and 3 days of treatment.
Immunohistochemistry
Paraffin embedded MTSs were cut in 4 μm sections.
Immunohistochemical staining were performed in a
Benchmark IHC/ISH (Ventana Medical Systems, Tucson,
Arizona) using a monoclonal antibody against γ-H2AX,
dilution 1:50, (Upstate, Charlottesville, Virginia). Stain-
ing were enzymatically developed with 3, 3-diaminoben-
zidine tetra hydrochloride (DAB) and counterstained with
hematoxylin.
Image analysis (γ-H2AX)
Images of MTS were acquired using a Spot Insight Colour
CCD camera (Diagnostic Instruments, Sterling Heights,
Michigan) coupled to a Nikon Eclipse E400, with a Nikon
10x objectives (Nikon Corporation, Tokyo, Japan) and
saved as 24-bit RGB TIFF.
The area of γ-H2AX positive cells in the viable part of the
MTS was determined using semi-automated image analy-
sis and compared to the total viable area. The image anal-
ysis software was written in Java™ as a plug-in to ImageJ.
The viable region of the MTS was selected manually and
the γ-H2AX positive cells were selected using a fixed
threshold in the blue channel.
Analysis of data
[18F]FDG uptake per viable volume of each MTS and γ-
H2AX positive area of each slice was normalized to the
control group. All data were analysed by ANOVA and
Dunnett's Multiple Comparison Test in Graph Pad Prism.
Results
Basic [18F]FDG experiments
The tumour cells formed multicellular spheroids about 1
day after seeding. Within the next day the characteristic
rounded shape with a rim of viable cells and a central
necrosis was observed.
When an increasing concentration of glucose was added
to the incubation medium, [18F]FDG uptake in MTSs
gradually decreased (Fig 1). The concentration inducing a
50% reduction compared to control was 10 mM. A
reduced temperature during the [18F]FDG incubation
reduced the [18F]FDG uptake by 77% (SE = 6%) (Fig 1).
These two observations indicate a saturable and tempera-
ture-dependent process for the [18F]FDG uptake and
hence exclude dominance by passive diffusion.
Effect of treatment observed in FDG-uptake in MTS of MCF-7 and BT474Figure 2
Effect of 3 days treatments with 1μM chemotherapy agents observed in FDG-uptake in MTS of MCF-7 and BT474.Page 4 of 8
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added to the incubation medium, [18F]FDG uptake signif-
icantly decreased; e.g., a 50% inhibition occurred at 12
μM (Fig 1). Addition of insulin to the incubation medium
increased the [18F]FDG uptake by 23% (SE = 5%) (Fig 1).
These two observations suggest glucose transport is the
dominant mechanism for [18F]FDG uptake in the MTSs.
[18F]FDG uptake alteration
• Paclitaxel and Docetaxel
Taxanes significantly reduced the uptake of [18F]FDG. The
decrease in uptake per viable volume was more evident in
BT474 (up to 55% decrease) than MCF-7 (up to 25%
reduction).
• Doxorubicin
Doxorubicin, which damages DNA by intercalation,
reduced [18F]FDG uptake per viable volume at the highest
dose, more noticeable in MCF-7 (25%) than in BT474
MTSs.
• Tamoxifen
Tamoxifen, an anti-oestrogen compound, reduced
[18F]FDG uptake per viable volume in MCF-7 at the high-
est dose of 1 μM.
• Imatinib
Imatinib, a tyrosine kinase inhibitor, slightly increased
[18F]FDG uptake in MCF-7 at the intermediate dose of
100 nM and 2 days follow up, otherwise no effect was
observed.
Figure 2 illustrates [18F]FDG uptake alteration in MTSs.
Immunohistochemistry
γH2AX formation in MCF-7 (Fig. 3) was considerably
increased in Taxanes- and Doxorubicin treated MTSs. In
BT-474 the increase was more noticeable in Doxorubicin
treated MTSs (Fig. 4).
Discussion
In order to explore if a range of conventional anti-cancer
drugs would impact on the cellular uptake of FDG, we uti-
lized multicellular tumour spheroids, treated with the
drugs and after a few days of treatment evaluated the
γH2AX staining in MTS of MCF-7Figure 3
γH2AX staining in MTS of MCF-7 after 3 days.Page 5 of 8
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selected with different characteristics. BT474 cells have
up-regulated mRNA and HER2/neu tyrosine kinase-
linked receptor protein in comparison to MCF7, while the
expression of the estrogen receptor alpha is known to be
up-regulated in MCF7 cells. These two cell-lines are
assumed to be representative for a variety of breast can-
cers.
Although growing cells as MTS is more laborious than
monolayer, MTS cells more closely mimic the real biolog-
ical environment by providing cell-to-cell adhesion and
signalling. This gives a more relevant picture of the drug
effects by including limitations in penetration, distribu-
tion and feedback mechanisms in cell signalling.
Here we established a new methodology for potential
drug screening by combining measurement of the mor-
phologic drug effect and evaluation of PET tracer uptake.
The method could serve dual purposes: to evaluate effects
of new drugs and to identify the optimal PET biomarker
for early evaluation of drug effect.
Initially we investigated the nature of [18F]FDG uptake in
MTS. We verified a reduced metabolism after either chal-
lenging with low temperature, or competition by unla-
beled glucose or inhibition with Cytochalasin-B. We also
observed a transport increase with insulin addition. These
sets of tests confirmed that in MCF-7 MTSs, [18F]FDG
accumulation is a biomarker which is related to transport
via the specific glucose transporters GLUT, followed by
phosphorylation by hexokinase.
An important aspect in the evaluation of chemotherapy
by PET-FDG is whether [18F]FDG can be used as a biomar-
ker to indicate treatment response. The accepted criterion
for treatment response is reduction in tumour size or ver-
ified lack of further growth. This can in turn relate to a
variety of functional aspects, such as induction of apopto-
sis, direct cell kill, effects on vascularity, reduced prolifer-
ation, remodelling of proportions of tumour and other
cells etc. These aspects do not necessarily relate to effects
on FDG uptake. E.g. transient increase in uptake of FDG
has been postulated to be an indication of a positive effect
causing a temporary inflammatory response, metabolic
flare. A retardation of cellular proliferation can be associ-
ated with a lack of effect on FDG uptake. Hence it is of
utmost importance to clarify the relation between antitu-
moral effects and effects on FDG uptake. For this, we
believe that MTS are the best in vitro cellular model,
allowing an easy evaluation of FDG uptake plus a means
Effect of treatment observed in γH2AX staining in MTS of MCF-7 and BT474Figure 4
Effect of 3 days treatments with 1μM chemotherapy agents, observed in γH2AX staining in MTS of MCF-7 and BT474.
Schematic of possible effect of chemotherapy treatmentFigure 5
Schematic of possible effect of chemotherapy treatment.Page 6 of 8
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ally associated with evaluations of apoptosis induction,
proliferation and other cellular biomarkers.
Paclitaxel and Docetaxel has a known activity against a
broad range of tumour types, including breast, ovarian,
lung, head and neck cancers [22-24]. These potent anti-
neoplastic drug binds to the N-terminal region of b-tubu-
lin and promotes the formation of highly stable microtu-
bules that resist depolymerization, thus preventing
normal cell division and arresting the cell cycle at the G2-
M phase [23-26]. Combining [18F]FDG-PET and image
analysis, we monitored the effect of Paclitaxel for 3 days
on two different human breast cancer line, in a concentra-
tion of 10 nM, 100 nM and 1 μM, added after 5 days of
growth as MTS. In BT474, we observed reduced glucose
transport per viable volume already at the lowest dose and
the shorter treatment time. The effect was more moderate
in MCF-7. These results indicate disturbance in cells phys-
iology as a consequence of the treatment with taxanes that
can be recorded with [18F]FDG-PET.
Doxorubicin is an anthracycline antibiotic produced by
the fungus streptomyces peucetius. It damages DNA by
intercalation of the anthracycline portion, metal ion che-
lation, or by generation of free radicals. Doxorubicin has
also been shown to inhibit DNA topoisomerase II which
is critical to DNA function [24]. Cytotoxic activity is not
specific to cell cycle phase [27]. Doxorubicin is also
known to be activated by mitochondrial electron trans-
port system and causes mitochondrial energy failure.
Thus, the effect might be not only by DNA damage, but
also by energy metabolism damage[28]. In our experi-
ments Doxorubicin decreased glucose transport at the
highest dose. The data suggest that [18F]FDG would record
an antitumoral effect of Doxorubicin in the early phase of
treatment at relevant doses. The effect of Doxorubicin was
more intense on MCF-7 than on BT474. γH2AX formation
that indicates DNA fragmentation [29] was drastically
increased in Doxorubicin treated BT474 MTSs. This radi-
cally alteration was not observed in FDG-uptake. It opens
the discussion if [18F]FDG is always the ideal biomarker
for follow-up of all category of anticancer treatment.
Tamoxifen is a synthetic non-steroidal anti-oestrogen. It is
thought to competitively block oestrogen receptors. Other
biochemical effects of Tamoxifen include interaction with
protein kinase C and stimulation of human NK cells
[23,24,30]. As expected, the effect of Tamoxifen can only
be observed in MCF-7. In our experiments the effect of
Tamoxifen can only be related to a glucose-transport alter-
ation [31].
Imatinib mesylate is a protein-tyrosine kinase inhibitor
that inhibits the Bcr-Abl tyrosine kinase, the constitutive
abnormal tyrosine kinase created by the Philadelphia
chromosome abnormality in chronic myeloid leukemia
(CML)[32]. It inhibits proliferation and induces apopto-
sis in Bcr-Abl positive cell lines as well as fresh leukemic
cells from Philadelphia chromosome positive chronic
myeloid leukemia [33].
Imatinib is not entirely selective; it also inhibits the recep-
tor tyrosine kinases for platelet-derived growth factor
(PDGF), stem cell factor (SCF), c-Kit and thereby inhibits
PDGF- and SCF-mediated cellular events [34]. In our
experiments no effect of Imatinib was observed.
Conclusion
To conclude, the combination of PET radiotracers, image
analysis of growth pattern and necrosis induction plus
histochemical analyses of proliferation and apoptosis in
MTSs provides a good model to evaluate the relationship
between tumour volume and the uptake of metabolic
tracer before and after chemotherapy. This feature could
be used for screening and selecting PET biomarkers for
early assessment of treatment response.
In addition, this new method gives a possibility to assess
quickly, and in vitro, a good preclinical profile of existing
and newly developed anti-cancer drugs.
Used clinically on biopsies, this method could potentially
be used on an individual level, first to select a treatment
for a particular patient, and then to select the PET tracer
for monitoring in a short follow up time the optimal drug
and dose regimen.
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